98 patents currently held

10 more in force are now held by other companies

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

1 more record may belong here and awaits a decision; it is not counted.

The next term ends in Feb 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.

Alerts on its grants, lapses and transfers.

Ending by 2030

Feb 2027

Next term end

Patent families

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027 2028 202920302031 2032 2033 2034 2035 2036 2037 2038 2039 2040 2041 2042 204320442045

notable patents fee due within 90 days all others Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank

Notable

Methods for Engineering Allogeneic and Immunosuppressive Resistant T Cell for Immunotherapy US 11,603,539

Cited by 89 later US patents, top 1% of utility patents granted in 2023 in our data. Protection runs to 2033.

Ends Sep 2033 · High confidence Also notable

Methods for Engineering T Cells for Immunotherapy by Using RNA-Guided Cas Nuclease System US 9,855,297

Cited by 109 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2034. A terminal disclaimer caps this term to an earlier patent's.

Ends Apr 2034 · High confidence Also notable

Method for Generating T-Cells Compatible for Allogenic Transplantation US 11,820,996

Cited by 19 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2038. A terminal disclaimer caps this term to an earlier patent's.

Ends May 2038 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Nov 28, 2026
The maintenance fee for Method to Overcome DNA Chemical Modifications Sensitivity of Engineered Tale DNA Binding Domains (US 10,301,614) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
3 fees due Dec 11 to 27, 2026 · next Dec 11
5 fees due Jan 4 to 30, 2027 · next Jan 4
1 fee due Feb 13, 2027
The maintenance fee for Methods for Modulating Tal Specificity (US 10,378,007) comes due Feb 13, 2027. Unpaid by Aug 13, 2027, it lapses early.
1 fee due Mar 26, 2027
The maintenance fee for New Sequence Specific Reagents Targeting CCR5 in Primary Hematopoietic Cells (US 11,767,512) comes due Mar 26, 2027. Unpaid by Sep 27, 2027, it lapses early.
2 fees due Apr 1 to 10, 2027 · next Apr 1
2 fees due May 12 to 21, 2027 · next May 12
4 fees due Jun 3 to 30, 2027 · next Jun 3
2 fees due Jul 16 to 28, 2027 · next Jul 16
3 fees due Aug 4 to 20, 2027 · next Aug 4
3 fees due Sep 1 to 10, 2027 · next Sep 1
3 fees due Oct 2 to 19, 2027 · next Oct 2

Which patents, and when each one lapses · Pro

Recent changes

2 of the patents on this record were granted since Aug 16, 2026

What they patent

The 5 largest of its 64 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Methods for Engineering Allogeneic and Immunosuppressive Resistant T Cell for Immunotherapy	16 in force	to Aug 2035
Methods for Engineering T Cells for Immunotherapy by Using RNA-Guided Cas Nuclease System	6 in force	to Jan 2036
CD123 Specific Chimeric Antigen Receptors for Cancer Immunotherapy	3 in force	to Mar 2035
Universal ANTI-CD22 Chimeric Antigen Receptor Engineered Immune Cells	2 in force	to Nov 2039
Targeted Gene Insertion for Improved Immune Cells Therapy	2 in force	to Sep 2039

Patents held now

Soonest term end first.

Patent	Title	Status	Expires	Confidence
US 7,824,901	Non-Uniform Electric Field Chamber for Cell Fusion held by Cellectis S.A. In force Term ends Feb 12, 2027 · High confidence	In force	Term ends Feb 12, 2027	High confidence
US 11,578,318	Large Volume Ex Vivo Electroporation Method held by Cellectis S.A. In force Term ends Nov 13, 2027 · High confidence	In force	Term ends Nov 13, 2027	High confidence
US 8,293,701	Methods and Compositions Relating to a Vaccine Against Prostate Cancer held by Cellectis S.A. In force Term ends Mar 20, 2028 · High confidence	In force	Term ends Mar 20, 2028	High confidence
US 7,897,372	I-Crei Meganuclease Variants with Modified Specificity, Method of Preparation and Uses Thereof held by Cellectis S.A. In force Term ends Apr 9, 2028 · High confidence	In force	Term ends Apr 9, 2028	High confidence
US 8,476,072	Meganuclease Recombination System In force Term ends Oct 23, 2029 · High confidence	In force	Term ends Oct 23, 2029	High confidence
US 9,365,864	Meganuclease Recombination System In force Term ends Oct 23, 2029 · High confidence	In force	Term ends Oct 23, 2029	High confidence
US 9,273,296	Meganuclease Variants Cleaving a DNA Target Sequence from a Glutamine Synthetase Gene and Uses Thereof In force Term ends Mar 13, 2031 · High confidence	In force	Term ends Mar 13, 2031	High confidence
US 10,494,626	Dynamic Mixing and Electroporation Chamber and System held by Cellectis S. A. In force Term ends Feb 21, 2032 · High confidence	In force	Term ends Feb 21, 2032	High confidence
US 11,136,566	Tale-Protein Scaffolds and Uses Thereof In force Term ends Apr 6, 2032 · High confidence	In force	Term ends Apr 6, 2032	High confidence
US 11,198,856	Method for the Generation of Compact Tale-Nucleases and Uses Thereof In force Term ends Aug 12, 2032 · High confidence	In force	Term ends Aug 12, 2032	High confidence

10 of 98 patents shown.

Pro members see all 98.

Pro members: see all 98 patents

Also on record, not counted in the 98: 10 patents in force now held by others · 23 patents ended · 36 applications pending · 111 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built

Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.

Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Cellectis